Neglected Patients Neglected diseases continue to cause significant morbidity and mortality in the developing world. Yet, of the 850 new therapeutic products approved between 2000 and 2011, only 4% (and only 1% of all approved NCEs) were indicated for neglected diseases, even though these diseases account for 11% of the global disease burden. Sleeping Sickness Sleeping sickness is endemic in 37 African countries. 13 million people are at medium to high risk of being infected. Leishmaniasis 350 million people are at risk of leishmaniasis worldwide. Visceral leishmaniasis kills an estimated 20,000-30,000 people annually. Chagas Disease Chagas disease is endemic in 21 Latin American countries where it kills more people than malaria. Less than 1% of patients have access to treatment. Paediatric HIV 2.1 million children below 15 years of age are living with HIV globally, mainly in sub-Saharan Africa, and 300 of them die every day. Filaria Disease 37 million people are infected with onchocerciasis (river blindness), and 169 million people are at risk. Mycetoma Stigmatizing disease often resulting in devastating deformities, amputation, and morbidity. Treatment success for eumycetoma is less than 35%. Hepatitis C 130-150 million people are living with chronic infection, of which 85% live in low- and middle-income countries. Antimicrobial Resistance GARDP was established as a joint initiative by WHO and DNDi to develop new treatments for drug-resistant infections.
